The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.
The approval was supported by positive 1-year data from the phase 3 Pavilion study in which patients with diabetic retinopathy (DR) who received Susvimo (ranibizumab injection) refilled every 9 months showed superior improvements on the Diabetic Retinopathy Severity Scale vs. patients treated with anti-VEGF injections.
No patients treated with Susvimo required supplemental treatment at 1 year, the release said.
Susvimo is delivered to the eye through the port delivery platform and is